Trends in anemia management in US hemodialysis patients 2004-2010

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Miskulin, Dana C ^a,h   Zhou, Jing ^b,e   Tangri, Navdeep ^c   Bandeen Roche, Karen ^d   Cook, Courtney ^b   Ephraim, Patti L ^d,e   Crews, Deidra C ^b,e   Scialla, Julia J ^f   Sozio, Stephen M ^b,e   Shafi, Tariq ^b,e   Jaar, Bernard G ^b,d,e,g   Boulware, L Ebony ^b,d,e  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g NEPHROLOGY CENTER OF MARYLAND   (United States)

^h TUFTS MEDICAL CENTER   (United States)

Author keywords

Anemia; Erythropoietin stimulating agents; Hemodialysis

Indexed keywords

FERROUS GLUCONATE; HEMOGLOBIN; IRON DEXTRAN; IRON SACCHARATE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; REIMBURSEMENT; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; CAUSALITY; COMORBIDITY; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SURVIVAL RATE; UNITED STATES; YOUNG ADULT;

EID: 84888325826     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-264     Document Type: Article

References (16)

1. Correction of anemia-payoffs and problems. Remuzzi G, Ingelfinger JR, N Engl J Med 2006 355 2144 2146 10.1056/NEJMe068233 17108347 (Pubitemid 44749323)
2. Erythropoiesis-stimulating agents-time for a reevaluation. Unger EF, Thompson AM, Blank MJ, Temple R, N Engl J Med 2010 362 189 192 10.1056/NEJMp0912328 20054037
3. US Renal Data System, USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2008
4. Correction of anemia with epoetin alfa in chronic kidney disease. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, Investigators C, N Engl J Med 2006 355 20 2085 2098 10.1056/NEJMoa065485 17108343 (Pubitemid 44749317)
5. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA, N Engl J Med 1998 339 584 590 10.1056/NEJM199808273390903 9718377 (Pubitemid 28385655)
6. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators, N Engl J Med 2006 355 20 2071 2084 10.1056/NEJMoa062276 17108342 (Pubitemid 44749316)
7. March 2007 PROCRIT® US PI including CHOIR and AOC updates. [ http://www.accessdata.fda.gov/drugsatfda-docs/label/2007/103234s5122lbl.pdf ] Accessed Nov 25, 2013
8. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR, Group DS, J Am Soc Nephrol 2007 18 3 975 984 10.1681/ASN.2006091034 17267740 (Pubitemid 46434515)
9. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators, N Engl J Med 2009 361 2019 2032 10.1056/NEJMoa0907845 19880844
10. FDA Drug Safety Communication, Modified dosing recommendations to improve the safe use of Erythropoiesis-Stimulating Agents (ESAs) in chronic kidney disease [ http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm ] (accessed Nov 25, 2013)
11. The Federal Register Vol. 75 No.155: 42 CFR Parts 410, 413 and 414 Medicare Program; End-Stage RenalDisease Prospective Payment System; Final Rule and Proposed Rule [ http://www.gpo.gov/fdsys/pkg/FR-2010-08-12/pdf/2010-18466. pdf ] (Accessed Nov 25, 2013)
12. U S Renal Data System, USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2012
13. Computerized decision support for EPO dosing in hemodialysis patients. Miskulin DC, Weiner DE, Tighiouart H, Ladik V, Servilla K, Zager PG, Martin A, Johnson HK, Meyer KB, Am J Kidney Dis 2009 54 1081 1088 10.1053/j.ajkd.2009.07. 010 19781831
14. The Federal Register Vol.76 No. 218. 42 CFR Parts 413 and 414 Medicare Program; End-Stage Renal Disease Prospective Payment System and Quality Incentive Program [ http://www.gpo.gov/fdsys/pkg/FR-2011-11-10/pdf/2011-28606. pdf ] (accessed July 2, 2013)
15. The DOPPS practice monitor for US dialysis care: trends through December 2011. Fuller DS, Pisoni R, Bieber BA, Gillespie B, Robinson B, Am J Kidney Dis 2013 61 342 346 10.1053/j.ajkd.2012.10.002 23127619
16. U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2013